Taking aspirin every other day slashes the risk of dying from breast or bladder cancer by up to a third, a new study claims.
The ‘wonderpill’ is already taken by millions of Brits to protect against heart disease.
Now, researchers have revealed that aspirin can also improve survival rates for some cancers, including bladder and breast.
Based on the findings, the researchers are calling for further population-based evidence to shed light on the potential protective effects of aspirin.
Taking aspirin every other day slashes the risk of dying from breast cancer by a quarter, a new study claims
Corresponding author Dr Holli Loomans-Kropp, of the National Cancer Institute in the United States, said: ‘The results add to accumulating evidence aspirin may improve survival for some cancers.
‘Although prior research has been most heavily concentrated in gastrointestinal cancers, our analysis extends the advantages to others, such as bladder and breast.’
Millions pop the over the counter painkiller daily to protect against heart disease. It thins the blood, reducing the risk of blood clots.
Its anti-inflammatory properties are also believed to reduce the risk of bowel cancer and some other forms of the disease.
The findings are based on a study of around 140,000 men and women in a cancer screening trial in the US, mostly over 65, who were tracked for up to 13 years.
They were asked about their aspirin intake, although not the size of the dose – typically 75mg in the UK.
Those with breast or bladder cancer who reported taking it at least three times a week were a quarter and a third less likely to die, respectively.
What’s more, any use reduced the risk of death from the diseases by 21 and 25 percent, respectively, compared to those who never had it.
Dr Loomans-Kropp said: ‘Although aspirin at least three times a week was associated with the strongest risk reduction, any use increased bladder and breast cancer survival.
‘These results may indicate that for some cancer types, aspirin may be advantageous. However, greater benefit may be observed with increased frequency of use.’
Experiments have suggested the drug combats inflammatory processes in breast and bladder cancers (stock image)
Experiments have suggested the drug combats inflammatory processes in breast and bladder cancers.
But it did not reduce the risk of them developing or treat or stop four other forms of the disease analysed – including cancers of the gullet, stomach, pancreas or womb.
Long-term aspirin use has been linked with decreased risk of heart disease, stroke, gastrointestinal cancers and death from any illness.
Dr Loomans-Kropp said: ‘Recent research suggests that aspirin use may offer protection against the development of and mortality from other cancer types as well.’
But the benefits and harms in older individuals is still debated. One study suggested it increased cancer mortality, but not incidence, in over 65s.
During the study period more than 32,500 cancers were diagnosed – including 4,552 of the breast and 1,751 of the bladder.
Dr Loomans-Kropp said: ‘Many studies have evaluated the long-term benefits of aspirin use.
‘However, the association of aspirin use with cancer incidence and survival in older individuals remains uncertain.
‘These findings suggest that aspirin use may improve bladder and breast cancer survival.’
But she added: ‘However, although aspirin use may confer a cancer protective effect, it remains necessary to consider the harms, as well as the benefits, of long-term aspirin use.’
The drug can cause dangerous stomach bleeds. The researchers called for further population-based evidence to shed light on the potential protective effects.
The findings were published in JAMA Network Open.